Amedeo Smart

Free Medical Literature Service


 

Amedeo

Colorectal Neoplasms

  Free Subscription

Articles published in
Br J Cancer
    July 2021
  1. ZABOROWSKI AM, Winter DC, Lynch L
    The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review.
    Br J Cancer. 2021 Jul 23. pii: 10.1038/s41416-021-01475.
    >> Share

  2. FURTADO FS, Suarez-Weiss KE, Vangel M, Clark JW, et al
    Clinical impact of PET/MRI in oligometastatic colorectal cancer.
    Br J Cancer. 2021 Jul 19. pii: 10.1038/s41416-021-01494.
    >> Share

  3. ZOLTICK ES, Smith-Warner SA, Yuan C, Wang M, et al
    Sugar-sweetened beverage, artificially sweetened beverage and sugar intake and colorectal cancer survival.
    Br J Cancer. 2021 Jul 15. pii: 10.1038/s41416-021-01487.
    >> Share

  4. TEN HOORN S, Sommeijer DW, Elliott F, Fisher D, et al
    Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone.
    Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01477.
    >> Share

  5. WANG X, Liu Q, Halfdanarson OO, Zoega H, et al
    Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study.
    Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01480.
    >> Share

  6. MORETTO R, Rossini D, Conca V, Lonardi S, et al
    CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
    Br J Cancer. 2021 Jul 12. pii: 10.1038/s41416-021-01483.
    >> Share

  7. HUA X, Kratz M, Malen RC, Dai JY, et al
    Association between post-treatment circulating biomarkers of inflammation and survival among stage II-III colorectal cancer patients.
    Br J Cancer. 2021 Jul 6. pii: 10.1038/s41416-021-01458.
    >> Share

    June 2021
  8. LEE KH, Chen WS, Jiang JK, Yang SH, et al
    The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon.
    Br J Cancer. 2021 Jun 29. pii: 10.1038/s41416-021-01470.
    >> Share

  9. LIN M, Fang Y, Li Z, Li Y, et al
    S100P contributes to promoter demethylation and transcriptional activation of SLC2A5 to promote metastasis in colorectal cancer.
    Br J Cancer. 2021 Jun 29. pii: 10.1038/s41416-021-01306.
    >> Share

  10. GUO F, De Brabander I, Francart J, Candeur M, et al
    Correction: Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.
    Br J Cancer. 2021 Jun 28. pii: 10.1038/s41416-021-01468.
    >> Share

  11. SEFRIOUI D, Beaussire L, Gillibert A, Blanchard F, et al
    CEA, CA19-9, circulating DNA and circulating tumour cell kinetics in patients treated for metastatic colorectal cancer (mCRC).
    Br J Cancer. 2021 Jun 10. pii: 10.1038/s41416-021-01431.
    >> Share

    May 2021
  12. OUAHOUD S, Jacobs RJ, Peppelenbosch MP, Fuhler GM, et al
    Correction: Kinome-wide analysis of the effect of statins in colorectal cancer.
    Br J Cancer. 2021 May 10. pii: 10.1038/s41416-021-01426.
    >> Share

  13. SALVIANTI F, Gelmini S, Mancini I, Pazzagli M, et al
    Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study.
    Br J Cancer. 2021 May 5. pii: 10.1038/s41416-021-01399.
    >> Share

  14. FRIEND T, Stebbing J
    Profiling circulating tumour cells and cell free DNA together in metastatic colon cancer.
    Br J Cancer. 2021 May 5. pii: 10.1038/s41416-021-01397.
    >> Share

    April 2021
  15. CHEN KH, Lin LI, Yuan CT, Tseng LH, et al
    Association between risk factors, molecular features and CpG island methylator phenotype colorectal cancer among different age groups in a Taiwanese cohort.
    Br J Cancer. 2021 Apr 12. pii: 10.1038/s41416-021-01300.
    >> Share

  16. LUND CM, Vistisen KK, Olsen AP, Bardal P, et al
    The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: a randomised trial (GERICO).
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01367.
    >> Share

  17. KIM DW, Tan E, Zhou JM, Schell MJ, et al
    A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer.
    Br J Cancer. 2021 Apr 7. pii: 10.1038/s41416-021-01368.
    >> Share

  18. BAXTER MA, Murphy J, Cameron D, Jordan J, et al
    The impact of COVID-19 on systemic anticancer treatment delivery in Scotland.
    Br J Cancer. 2021;124:1353-1356.
    >> Share

  19. KREGTING LM, Kaljouw S, de Jonge L, Jansen EEL, et al
    Effects of cancer screening restart strategies after COVID-19 disruption.
    Br J Cancer. 2021;124:1516-1523.
    >> Share

    March 2021
  20. FEARON DT, Janowitz T
    AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.
    Br J Cancer. 2021 Mar 26. pii: 10.1038/s41416-021-01315.
    >> Share

  21. GOLDER AM, McMillan DC, Park JH, Mansouri D, et al
    The prognostic value of combined measures of the systemic inflammatory response in patients with colon cancer: an analysis of 1700 patients.
    Br J Cancer. 2021 Mar 24. pii: 10.1038/s41416-021-01308.
    >> Share

  22. OUAHOUD S, Jacobs RJ, Peppelenbosch MP, Fuhler GM, et al
    Kinome-wide analysis of the effect of statins in colorectal cancer.
    Br J Cancer. 2021 Mar 19. pii: 10.1038/s41416-021-01318.
    >> Share

  23. ROSENDAHL HUBER A, Pleguezuelos-Manzano C, Puschhof J
    A bacterial mutational footprint in colorectal cancer genomes.
    Br J Cancer. 2021 Mar 19. pii: 10.1038/s41416-021-01273.
    >> Share

  24. YAEGASHI M, Iwaya T, Sasaki N, Fujita M, et al
    Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling.
    Br J Cancer. 2021 Mar 3. pii: 10.1038/s41416-021-01266.
    >> Share

    February 2021
  25. SHANG Y, Zhang X, Lu L, Jiang K, et al
    Pharmaceutical immunoglobulin G impairs anti-carcinoma activity of oxaliplatin in colon cancer cells.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01272.
    >> Share

  26. PINTO-FERNANDEZ A, Salio M, Partridge T, Chen J, et al
    Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity.
    Br J Cancer. 2021;124:817-830.
    >> Share

    January 2021
  27. ZHANG X, Theodoratou E, Li X, Farrington SM, et al
    Genetically predicted physical activity levels are associated with lower colorectal cancer risk: a Mendelian randomisation study.
    Br J Cancer. 2021 Jan 29. pii: 10.1038/s41416-020-01236.
    >> Share

  28. BAILEY SER, Abel GA, Atkins A, Byford R, et al
    Diagnostic performance of a faecal immunochemical test for patients with low-risk symptoms of colorectal cancer in primary care: an evaluation in the South West of England.
    Br J Cancer. 2021 Jan 19. pii: 10.1038/s41416-020-01221.
    >> Share

  29. UENO H, Ishiguro M, Nakatani E, Ishikawa T, et al
    Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial).
    Br J Cancer. 2021 Jan 7. pii: 10.1038/s41416-020-01222.
    >> Share

  30. CULLIFORD R, Cornish AJ, Law PJ, Farrington SM, et al
    Lack of an association between gallstone disease and bilirubin levels with risk of colorectal cancer: a Mendelian randomisation analysis.
    Br J Cancer. 2021 Jan 7. pii: 10.1038/s41416-020-01211.
    >> Share

  31. BRAGAGNOLI AC, Araujo RLC, Ferraz MW, Dos Santos LV, et al
    Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial.
    Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01208.
    >> Share

    December 2020
  32. LOUGHREY MB, Fisher NC, McCooey AJ, Dunne PD, et al
    Comment on "Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes".
    Br J Cancer. 2020 Dec 14. pii: 10.1038/s41416-020-01213.
    >> Share

  33. YASUI K, Shida D, Nakamura Y, Ahiko Y, et al
    Postoperative, but not preoperative, inflammation-based prognostic markers are prognostic factors in stage III colorectal cancer patients.
    Br J Cancer. 2020 Dec 1. pii: 10.1038/s41416-020-01189.
    >> Share

  34. ZELLWEGER M, Gonzalez M
    Comment on: the myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:1833-1834.
    >> Share

  35. MACBETH F, Fallowfield DL
    Reply to 'Comment on "The myth of pulmonary metastasectomy'".
    Br J Cancer. 2020;123:1835-1836.
    >> Share

    November 2020
  36. YU J, Li S, Xu Z, Guo J, et al
    CDX2 inhibits epithelial-mesenchymal transition in colorectal cancer by modulation of Snail expression and beta-catenin stabilisation via transactivation of PTEN expression.
    Br J Cancer. 2020 Nov 26. pii: 10.1038/s41416-020-01148.
    >> Share

  37. ALEXANDER PG, Roseweir AK, Pennel KAF, van Wyk HC, et al
    The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.
    Br J Cancer. 2020 Nov 23. pii: 10.1038/s41416-020-01168.
    >> Share

  38. JACOME AA, Vreeland TJ, Johnson B, Kawaguchi Y, et al
    The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients.
    Br J Cancer. 2020 Nov 19. pii: 10.1038/s41416-020-01169.
    >> Share

  39. HUIJBERTS SCFA, Boelens MC, Bernards R, Opdam FL, et al
    Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib.
    Br J Cancer. 2020 Nov 18. pii: 10.1038/s41416-020-01147.
    >> Share

  40. HEINEMANN V, von Weikersthal LF, Decker T, Kiani A, et al
    FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
    Br J Cancer. 2020 Nov 6. pii: 10.1038/s41416-020-01140.
    >> Share

  41. FANG Z, He M, Song M
    Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank.
    Br J Cancer. 2020 Nov 3. pii: 10.1038/s41416-020-01143.
    >> Share

  42. LI YY, Gao LJ, Zhang YX, Liu SJ, et al
    Bisphosphonates and risk of cancers: a systematic review and meta-analysis.
    Br J Cancer. 2020;123:1570-1581.
    >> Share

    October 2020
  43. CHA PH, Hwang JH, Kwak DK, Koh E, et al
    APC loss induces Warburg effect via increased PKM2 transcription in colorectal cancer.
    Br J Cancer. 2020 Oct 19. pii: 10.1038/s41416-020-01118.
    >> Share

  44. WENSINK GE, Elferink MAG, May AM, Mol L, et al
    Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.
    Br J Cancer. 2020 Oct 13. pii: 10.1038/s41416-020-01076.
    >> Share

  45. ROSSINI D, Lonardi S, Antoniotti C, Santini D, et al
    Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01089.
    >> Share

  46. HE F, Ju HQ, Ding Y, Jiang Z, et al
    Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection.
    Br J Cancer. 2020;123:1244-1252.
    >> Share

    September 2020
  47. SIMIN J, Fornes R, Liu Q, Olsen RS, et al
    Antibiotic use and risk of colorectal cancer: a systematic review and dose-response meta-analysis.
    Br J Cancer. 2020 Sep 24. pii: 10.1038/s41416-020-01082.
    >> Share

  48. VAUGHAN-SHAW PG, Buijs LF, Blackmur JP, Theodoratou E, et al
    The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials.
    Br J Cancer. 2020 Sep 15. pii: 10.1038/s41416-020-01060.
    >> Share

  49. PAPE J, Magdeldin T, Stamati K, Nyga A, et al
    Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma.
    Br J Cancer. 2020;123:1178-1190.
    >> Share

  50. MURAHASHI S, Akiyoshi T, Sano T, Fukunaga Y, et al
    Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence.
    Br J Cancer. 2020;123:803-810.
    >> Share

    August 2020
  51. MASUISHI T, Tsuji A, Kotaka M, Nakamura M, et al
    Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08.
    Br J Cancer. 2020 Aug 31. pii: 10.1038/s41416-020-01042.
    >> Share

  52. COWLING TE, Bellot A, Boyle J, Walker K, et al
    One-year mortality of colorectal cancer patients: development and validation of a prediction model using linked national electronic data.
    Br J Cancer. 2020 Aug 24. pii: 10.1038/s41416-020-01034.
    >> Share

  53. KIM TW, Lee YS, Yun NH, Shin CH, et al
    Correction: MicroRNA-17-5p regulates EMT by targeting vimentin in colorectal cancer.
    Br J Cancer. 2020 Aug 20. pii: 10.1038/s41416-020-1027.
    >> Share

  54. MACBETH F, Fallowfield L
    The myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:499-500.
    >> Share

    July 2020
  55. RAGHAV K, Shen JP, Jacome AA, Guerra JL, et al
    Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer.
    Br J Cancer. 2020 Jul 31. pii: 10.1038/s41416-020-1015.
    >> Share

  56. CRAIG SG, Humphries MP, Alderdice M, Bingham V, et al
    Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia.
    Br J Cancer. 2020 Jul 20. pii: 10.1038/s41416-020-0985.
    >> Share

  57. YANG L, Chen P, Zhang L, Wang L, et al
    Prognostic value of nucleotyping, DNA ploidy and stroma in high-risk stage II colon cancer.
    Br J Cancer. 2020 Jul 6. pii: 10.1038/s41416-020-0974.
    >> Share

  58. YUAN C, Ng K
    Vitamin D supplementation: a potential therapeutic agent for metastatic colorectal cancer.
    Br J Cancer. 2020 Jul 6. pii: 10.1038/s41416-020-0958.
    >> Share

  59. HOPPENER DJ, Nierop PMH, Hof J, Sideras K, et al
    Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis.
    Br J Cancer. 2020;123:196-206.
    >> Share

    June 2020
  60. IWAMOTO K, Takahashi H, Okuzaki D, Osawa H, et al
    Syntenin-1 promotes colorectal cancer stem cell expansion and chemoresistance by regulating prostaglandin E2 receptor.
    Br J Cancer. 2020 Jun 29. pii: 10.1038/s41416-020-0965.
    >> Share

  61. KIM TW, Lee YS, Yun NH, Shin CH, et al
    MicroRNA-17-5p regulates EMT by targeting vimentin in colorectal cancer.
    Br J Cancer. 2020 Jun 17. pii: 10.1038/s41416-020-0940.
    >> Share

  62. BABIC A, Zhang X, Morales-Oyarvide V, Yuan C, et al
    Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies.
    Br J Cancer. 2020 Jun 16. pii: 10.1038/s41416-020-0939.
    >> Share

  63. PERNOT S, Pellerin O, Artru P, Monterymard C, et al
    Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.
    Br J Cancer. 2020 Jun 8. pii: 10.1038/s41416-020-0917.
    >> Share

  64. PARK JW, Chang HJ, Yeo HY, Han N, et al
    The relationships between systemic cytokine profiles and inflammatory markers in colorectal cancer and the prognostic significance of these parameters.
    Br J Cancer. 2020 Jun 3. pii: 10.1038/s41416-020-0924.
    >> Share

  65. ROOS VH, Kallenberg FGJ, van der Vlugt M, Bongers EJC, et al
    Addition of an online, validated family history questionnaire to the Dutch FIT-based screening programme did not improve its diagnostic yield.
    Br J Cancer. 2020;122:1865-1871.
    >> Share

    May 2020
  66. RAY AL, Nofchissey RA, Khan MA, Reidy MA, et al
    The role of sex in the innate and adaptive immune environment of metastatic colorectal cancer.
    Br J Cancer. 2020 May 26. pii: 10.1038/s41416-020-0913.
    >> Share

  67. WANG K, Song K, Ma Z, Yao Y, et al
    Identification of EMT-related high-risk stage II colorectal cancer and characterisation of metastasis-related genes.
    Br J Cancer. 2020 May 21. pii: 10.1038/s41416-020-0902.
    >> Share

  68. FUCA G, Guarini V, Antoniotti C, Morano F, et al
    The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
    Br J Cancer. 2020 May 19. pii: 10.1038/s41416-020-0894.
    >> Share

  69. LOKTIONOV A, Soubieres A, Bandaletova T, Francis N, et al
    Biomarker measurement in non-invasively sampled colorectal mucus as a novel approach to colorectal cancer detection: screening and triage implications.
    Br J Cancer. 2020 May 13. pii: 10.1038/s41416-020-0893.
    >> Share

  70. STREMITZER S, Vermeulen P, Graver S, Kockx M, et al
    Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases.
    Br J Cancer. 2020;122:1518-1524.
    >> Share

  71. QIN B, Zou S, Li K, Wang H, et al
    CSN6-TRIM21 axis instigates cancer stemness during tumorigenesis.
    Br J Cancer. 2020;122:1673-1685.
    >> Share

    April 2020
  72. BARISCIANO G, Colangelo T, Rosato V, Muccillo L, et al
    Correction: miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer.
    Br J Cancer. 2020 Apr 17. pii: 10.1038/s41416-020-0855.
    >> Share

  73. DAI W, Wang G, Chwa J, Oh ME, et al
    Mitochondrial division inhibitor (mdivi-1) decreases oxidative metabolism in cancer.
    Br J Cancer. 2020;122:1288-1297.
    >> Share

  74. VAN GEEL RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, et al
    Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
    Br J Cancer. 2020;122:1166-1174.
    >> Share

    March 2020
  75. MILANO G, Gal J
    Comment on: "Exploring the best treatment options for BRAF-mutant metastatic colon cancer".
    Br J Cancer. 2020 Mar 31. pii: 10.1038/s41416-020-0819.
    >> Share

  76. AMITAY EL, Carr PR, Jansen L, Roth W, et al
    Smoking, alcohol consumption and colorectal cancer risk by molecular pathological subtypes and pathways.
    Br J Cancer. 2020 Mar 30. pii: 10.1038/s41416-020-0803.
    >> Share

  77. WANG X, Li D, Sun L, Shen G, et al
    Regulation of the small GTPase Ran by miR-802 modulates proliferation and metastasis in colorectal cancer cells.
    Br J Cancer. 2020 Mar 25. pii: 10.1038/s41416-020-0809.
    >> Share

  78. YUAN Z, Liang X, Zhan Y, Wang Z, et al
    Targeting CD133 reverses drug-resistance via the AKT/NF-kappaB/MDR1 pathway in colorectal cancer.
    Br J Cancer. 2020 Mar 16. pii: 10.1038/s41416-020-0783.
    >> Share

  79. USHER-SMITH JA, Harshfield A, Saunders CL, Sharp SJ, et al
    Correction: External validation of risk prediction models for incident colorectal cancer using UK Biobank.
    Br J Cancer. 2020 Mar 12. pii: 10.1038/s41416-020-0767.
    >> Share

  80. HARUKI K, Kosumi K, Li P, Arima K, et al
    An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer.
    Br J Cancer. 2020 Mar 11. pii: 10.1038/s41416-020-0780.
    >> Share

  81. BARNES EME, Xu Y, Benito A, Herendi L, et al
    Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells.
    Br J Cancer. 2020 Mar 10. pii: 10.1038/s41416-020-0777.
    >> Share

  82. BARISCIANO G, Colangelo T, Rosato V, Muccillo L, et al
    miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer.
    Br J Cancer. 2020 Mar 5. pii: 10.1038/s41416-020-0773.
    >> Share

  83. OTANDAULT A, Abraham JD, Al Amir Dache Z, Khalyfa A, et al
    Hypoxia differently modulates the release of mitochondrial and nuclear DNA.
    Br J Cancer. 2020;122:715-725.
    >> Share

  84. HERIOT AG
    Whither Anal Cancer?
    Br J Cancer. 2020;122:733-734.
    >> Share

  85. SEKHAR H, Malcomson L, Kochhar R, Sperrin M, et al
    Temporal improvements in loco-regional failure and survival in patients with anal cancer treated with chemo-radiotherapy: treatment cohort study (1990-2014).
    Br J Cancer. 2020;122:749-758.
    >> Share

  86. APARICIO T, Bennouna J, Le Malicot K, Boige V, et al
    Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.
    Br J Cancer. 2020;122:957-962.
    >> Share

    February 2020
  87. BANDO H, Kagawa Y, Kato T, Akagi K, et al
    Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.
    Br J Cancer. 2020 Feb 25. pii: 10.1038/s41416-020-0766.
    >> Share

  88. MORIMOTO Y, Mizushima T, Wu X, Okuzaki D, et al
    miR-4711-5p regulates cancer stemness and cell cycle progression via KLF5, MDM2 and TFDP1 in colon cancer cells.
    Br J Cancer. 2020 Feb 18. pii: 10.1038/s41416-020-0758.
    >> Share

  89. GUO F, De Brabander I, Francart J, Candeur M, et al
    Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.
    Br J Cancer. 2020 Feb 18. pii: 10.1038/s41416-020-0754.
    >> Share

  90. VAN DE BEEK I, Glykofridis IE, Wolthuis RMF, Gille HJJP, et al
    No evidence for increased prevalence of colorectal carcinoma in 399 Dutch patients with Birt-Hogg-Dube syndrome.
    Br J Cancer. 2020;122:590-594.
    >> Share

    January 2020
  91. ARMSTRONG D, Dregan A, Ashworth M, White P, et al
    The association between colorectal cancer and prior antibiotic prescriptions: case control study.
    Br J Cancer. 2020 Jan 13. pii: 10.1038/s41416-019-0701.
    >> Share

  92. LIANG Y, Zhu D, Hou L, Wang Y, et al
    MiR-107 confers chemoresistance to colorectal cancer by targeting calcium-binding protein 39.
    Br J Cancer. 2020 Jan 10. pii: 10.1038/s41416-019-0703.
    >> Share

    December 2019
  93. HOU P, Shi P, Jiang T, Yin H, et al
    DKC1 enhances angiogenesis by promoting HIF-1alpha transcription and facilitates metastasis in colorectal cancer.
    Br J Cancer. 2019 Dec 20. pii: 10.1038/s41416-019-0695.
    >> Share

  94. WU L, Zhou Z, Han S, Chen J, et al
    PLAGL2 promotes epithelial-mesenchymal transition and mediates colorectal cancer metastasis via beta-catenin-dependent regulation of ZEB1.
    Br J Cancer. 2019 Dec 12. pii: 10.1038/s41416-019-0679.
    >> Share

  95. FU M, Chen D, Luo F, Li M, et al
    Association of the tumour stroma percentage in the preoperative biopsies with lymph node metastasis in colorectal cancer.
    Br J Cancer. 2019 Dec 2. pii: 10.1038/s41416-019-0671.
    >> Share

    October 2019
  96. KUWAHARA T, Hazama S, Suzuki N, Yoshida S, et al
    Correction: Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
    Br J Cancer. 2019 Oct 17. pii: 10.1038/s41416-019-0605.
    >> Share

  97. SAHIN IH, Akce M, Alese O, Shaib W, et al
    Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms.
    Br J Cancer. 2019 Oct 14. pii: 10.1038/s41416-019-0599.
    >> Share

    September 2019
  98. CIRONE M, Lotti LV, Granato M, Renzo LD, et al
    Sourcing the immune system to induce immunogenic cell death in Kras-colorectal cancer cells.
    Br J Cancer. 2019 Sep 27. pii: 10.1038/s41416-019-0561.
    >> Share

  99. DASHTI SG, Li WY, Buchanan DD, Clendenning M, et al
    Type 2 diabetes mellitus, blood cholesterol, triglyceride and colorectal cancer risk in Lynch syndrome.
    Br J Cancer. 2019 Sep 25. pii: 10.1038/s41416-019-0580.
    >> Share

  100. GLAIRE MA, Domingo E, Sveen A, Bruun J, et al
    Correction: Tumour-infiltrating CD8(+) lymphocytes and colorectal cancer recurrence by tumour and nodal stage.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0590.
    >> Share

  101. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
    Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
    >> Share

  102. KUWAHARA T, Hazama S, Suzuki N, Yoshida S, et al
    Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
    Br J Cancer. 2019 Sep 6. pii: 10.1038/s41416-019-0559.
    >> Share

  103. LOUPAKIS F, Biason P, Prete AA, Cremolini C, et al
    CK7 and consensus molecular subtypes as major prognosticators in (V600E)BRAF mutated metastatic colorectal cancer.
    Br J Cancer. 2019 Sep 2. pii: 10.1038/s41416-019-0560.
    >> Share

    August 2019
  104. KORPHAISARN K, Morris V, Davis JS, Overman MJ, et al
    Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.
    Br J Cancer. 2019 Aug 13. pii: 10.1038/s41416-019-0548.
    >> Share

  105. GLAIRE MA, Domingo E, Sveen A, Bruun J, et al
    Tumour-infiltrating CD8(+) lymphocytes and colorectal cancer recurrence by tumour and nodal stage.
    Br J Cancer. 2019 Aug 7. pii: 10.1038/s41416-019-0540.
    >> Share

    July 2019
  106. ELEZ E, Pericay C, Valladares-Ayerbes M, Bando I, et al
    A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
    Br J Cancer. 2019 Jul 31. pii: 10.1038/s41416-019-0537.
    >> Share

  107. PFUDERER PL, Ballhausen A, Seidler F, Stark HJ, et al
    High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer.
    Br J Cancer. 2019 Jul 30. pii: 10.1038/s41416-019-0514.
    >> Share

  108. TAIEB J, Lapeyre-Prost A, Laurent Puig P, Zaanan A, et al
    Exploring the best treatment options for BRAF-mutant metastatic colon cancer.
    Br J Cancer. 2019 Jul 29. pii: 10.1038/s41416-019-0526.
    >> Share

  109. GORBUNOVA V, Beck JT, Hofheinz RD, Garcia-Alfonso P, et al
    Correction: A phase 2 randomised study of veliparib plus FOLFIRI+/-bevacizumab versus placebo plus FOLFIRI+/-bevacizumab in metastatic colorectal cancer.
    Br J Cancer. 2019 Jul 26. pii: 10.1038/s41416-019-0528.
    >> Share

  110. KROUPA M, Rachakonda SK, Liska V, Srinivas N, et al
    Relationship of telomere length in colorectal cancer patients with cancer phenotype and patient prognosis.
    Br J Cancer. 2019 Jul 17. pii: 10.1038/s41416-019-0525.
    >> Share

  111. AUCLIN E, Andre T, Taieb J, Banzi M, et al
    Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.
    Br J Cancer. 2019 Jul 12. pii: 10.1038/s41416-019-0521.
    >> Share

  112. MEZHEYEUSKI A, Hrynchyk I, Herrera M, Karlberg M, et al
    Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer.
    Br J Cancer. 2019 Jul 10. pii: 10.1038/s41416-019-0519.
    >> Share

  113. OKI E, Emi Y, Yamanaka T, Uetake H, et al
    Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).
    Br J Cancer. 2019;121:222-229.
    >> Share

  114. REZENDE LFM, Lee DH, Keum N, Nimptsch K, et al
    Physical activity during adolescence and risk of colorectal adenoma later in life: results from the Nurses' Health Study II.
    Br J Cancer. 2019;121:86-94.
    >> Share

    May 2019
  115. CHARITOU T, Srihari S, Lynn MA, Jarboui MA, et al
    Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRAS(G13D) mutation.
    Br J Cancer. 2019 May 28. pii: 10.1038/s41416-019-0477.
    >> Share

  116. SYRIOPOULOU E, Morris E, Finan PJ, Lambert PC, et al
    Understanding the impact of socioeconomic differences in colorectal cancer survival: potential gain in life-years.
    Br J Cancer. 2019 May 1. pii: 10.1038/s41416-019-0455.
    >> Share

    April 2019
  117. BANDO H, Kagawa Y, Kato T, Akagi K, et al
    A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer.
    Br J Cancer. 2019 Apr 24. pii: 10.1038/s41416-019-0457.
    >> Share

  118. NAGATA H, Ishihara S, Abe H, Ushiku T, et al
    LGR5 expression predicts peritoneal recurrence after curative resection of primary colon cancer.
    Br J Cancer. 2019 Apr 19. pii: 10.1038/s41416-019-0442.
    >> Share

  119. XU X, Zhu L, Yang Y, Pan Y, et al
    Low tumour PPM1H indicates poor prognosis in colorectal cancer via activation of cancer-associated fibroblasts.
    Br J Cancer. 2019 Apr 16. pii: 10.1038/s41416-019-0450.
    >> Share

  120. MOON JH, Hong SW, Kim JE, Shin JS, et al
    Targeting beta-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations.
    Br J Cancer. 2019 Apr 4. pii: 10.1038/s41416-019-0434.
    >> Share

  121. KATHER JN, Halama N
    Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer.
    Br J Cancer. 2019 Apr 2. pii: 10.1038/s41416-019-0441.
    >> Share

  122. STROWITZKI MJ, Radhakrishnan P, Pavicevic S, Scheer J, et al
    High hepatic expression of PDK4 improves survival upon multimodal treatment of colorectal liver metastases.
    Br J Cancer. 2019;120:675-688.
    >> Share

    March 2019
  123. OH HJ, Bae JM, Wen X, Jung S, et al
    p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Br J Cancer. 2019 Mar 21. pii: 10.1038/s41416-019-0429.
    >> Share

  124. IJSSELSTEIJN ME, Petitprez F, Lacroix L, Ruano D, et al
    Revisiting immune escape in colorectal cancer in the era of immunotherapy.
    Br J Cancer. 2019 Mar 13. pii: 10.1038/s41416-019-0421.
    >> Share

  125. TOMITA N, Kunieda K, Maeda A, Hamada C, et al
    Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study.
    Br J Cancer. 2019 Mar 5. pii: 10.1038/s41416-019-0410.
    >> Share

  126. MARTIN V, Chiriaco C, Modica C, Acquadro A, et al
    Met inhibition revokes IFNgamma-induction of PD-1 ligands in MET-amplified tumours.
    Br J Cancer. 2019;120:527-536.
    >> Share

    February 2019
  127. RASMUSSEN S, Haastrup PF, Balasubramaniam K, Elnegaard S, et al
    Predictive values of colorectal cancer alarm symptoms in the general population: a nationwide cohort study.
    Br J Cancer. 2019 Feb 22. pii: 10.1038/s41416-019-0385.
    >> Share

    January 2019
  128. VARKARIS A, Katsiampoura A, Davis JS, Shah N, et al
    Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.
    Br J Cancer. 2019 Jan 14. pii: 10.1038/s41416-018-0360.
    >> Share

  129. GOEPPERT B, Roessler S, Renner M, Singer S, et al
    Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma.
    Br J Cancer. 2019;120:109-114.
    >> Share

    December 2018
  130. PAEZ D, Tobena M, Fernandez-Plana J, Sebio A, et al
    Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
    Br J Cancer. 2018 Dec 26. pii: 10.1038/s41416-018-0348.
    >> Share

  131. CROSS AJ, Wooldrage K, Robbins EC, Pack K, et al
    Whole-colon investigation vs. flexible sigmoidoscopy for suspected colorectal cancer based on presenting symptoms and signs: a multicentre cohort study.
    Br J Cancer. 2018 Dec 19. pii: 10.1038/s41416-018-0335.
    >> Share

  132. SIRNIO P, Vayrynen JP, Klintrup K, Makela J, et al
    Alterations in serum amino-acid profile in the progression of colorectal cancer: associations with systemic inflammation, tumour stage and patient survival.
    Br J Cancer. 2018 Dec 19. pii: 10.1038/s41416-018-0357.
    >> Share

  133. WANG J, Shibayama Y, Zhang A, Ohsaki H, et al
    (Pro)renin receptor promotes colorectal cancer through the Wnt/beta-catenin signalling pathway despite constitutive pathway component mutations.
    Br J Cancer. 2018 Dec 17. pii: 10.1038/s41416-018-0350.
    >> Share

  134. GORBUNOVA V, Beck JT, Hofheinz RD, Garcia-Alfonso P, et al
    A phase 2 randomised study of veliparib plus FOLFIRI+/-bevacizumab versus placebo plus FOLFIRI+/-bevacizumab in metastatic colorectal cancer.
    Br J Cancer. 2018 Dec 11. pii: 10.1038/s41416-018-0343.
    >> Share

    November 2018
  135. LOUPAKIS F, Hurwitz HI, Saltz L, Arnold D, et al
    Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer.
    Br J Cancer. 2018 Nov 29. pii: 10.1038/s41416-018-0304.
    >> Share

  136. GILBERT DC, Wakeham K, Langley RE, Vale CL, et al
    Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis.
    Br J Cancer. 2018 Nov 28. pii: 10.1038/s41416-018-0273.
    >> Share

  137. GARCIA-FONCILLAS J, Tabernero J, Elez E, Aranda E, et al
    Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer.
    Br J Cancer. 2018 Nov 23. pii: 10.1038/s41416-018-0293.
    >> Share

  138. HANSEN TF, Kjaer-Frifeldt S, Eriksen AC, Lindebjerg J, et al
    Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts.
    Br J Cancer. 2018 Nov 14. pii: 10.1038/s41416-018-0285.
    >> Share

  139. ROBLES-ZURITA J, Boyd KA, Briggs AH, Iveson T, et al
    SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.
    Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0319.
    >> Share

  140. KIM BK, Nam SW, Min BS, Ban HS, et al
    Bcl-2-dependent synthetic lethal interaction of the IDF-11774 with the V0 subunit C of vacuolar ATPase (ATP6V0C) in colorectal cancer.
    Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0289.
    >> Share

  141. MA Y, Yang W, Song M, Smith-Warner SA, et al
    Type 2 diabetes and risk of colorectal cancer in two large U.S. prospective cohorts.
    Br J Cancer. 2018 Nov 7. pii: 10.1038/s41416-018-0314.
    >> Share

  142. TRINH A, Ladrach C, Dawson HE, Ten Hoorn S, et al
    Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.
    Br J Cancer. 2018 Nov 2. pii: 10.1038/s41416-018-0230.
    >> Share

    October 2018
  143. SCHIFFMANN LM, Fritsch M, Gebauer F, Gunther SD, et al
    Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
    Br J Cancer. 2018 Oct 31. pii: 10.1038/s41416-018-0198.
    >> Share

  144. AL-SAFFAR NMS, Troy H, Wong Te Fong AC, Paravati R, et al
    Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma.
    Br J Cancer. 2018 Oct 31. pii: 10.1038/s41416-018-0242.
    >> Share

  145. SMITH T, Gunter MJ, Tzoulaki I, Muller DC, et al
    The added value of genetic information in colorectal cancer risk prediction models: development and evaluation in the UK Biobank prospective cohort study.
    Br J Cancer. 2018 Oct 16. pii: 10.1038/s41416-018-0282.
    >> Share

  146. BARTOLOME RA, Jaen M, Casal JI
    An IL13Ralpha2 peptide exhibits therapeutic activity against metastatic colorectal cancer.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0259.
    >> Share

  147. UZUNPARMAK B, Sahin IH
    Comment on "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer".
    Br J Cancer. 2018 Oct 9. pii: 10.1038/s41416-018-0279.
    >> Share

  148. ROSEWEIR AK, McMillan DC, Edwards J
    Reply to comment of "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer".
    Br J Cancer. 2018 Oct 9. pii: 10.1038/s41416-018-0275.
    >> Share

  149. HALIM S, Markert EK, Vazquez A
    Analysis of cell proliferation and tissue remodelling uncovers a KLF4 activity score associated with poor prognosis in colorectal cancer.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0253.
    >> Share

  150. BRENNER H, Chen C
    The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention.
    Br J Cancer. 2018 Oct 4. pii: 10.1038/s41416-018-0264.
    >> Share

  151. CARVAJAL-CARMONA LG
    Moving the needle on colorectal cancer genetics: it takes more than two to TANGO.
    Br J Cancer. 2018 Oct 4. pii: 10.1038/s41416-018-0219.
    >> Share

    August 2018
  152. THEODORATOU E, Farrington SM, Timofeeva M, Din FV, et al
    Genome-wide scan of the effect of common nsSNPs on colorectal cancer survival outcome.
    Br J Cancer. 2018 Aug 21. pii: 10.1038/s41416-018-0117.
    >> Share

  153. MARINGE C, Rachet B, Lyratzopoulos G, Rubio FJ, et al
    Persistent inequalities in unplanned hospitalisation among colon cancer patients across critical phases of their care pathway, England, 2011-13.
    Br J Cancer. 2018 Aug 15. pii: 10.1038/s41416-018-0170.
    >> Share

  154. SUGIMACHI K, Sakimura S, Kuramitsu S, Hirata H, et al
    Serial mutational tracking in surgically resected locally advanced colorectal cancer with neoadjuvant chemotherapy.
    Br J Cancer. 2018 Aug 3. pii: 10.1038/s41416-018-0208.
    >> Share

  155. JUUL JS, Hornung N, Andersen B, Laurberg S, et al
    The value of using the faecal immunochemical test in general practice on patients presenting with non-alarm symptoms of colorectal cancer.
    Br J Cancer. 2018 Aug 1. pii: 10.1038/s41416-018-0178.
    >> Share

    July 2018
  156. PERNOT S, Boucheron P, Pere H, Lucas ML, et al
    Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men.
    Br J Cancer. 2018 Jul 20. pii: 10.1038/s41416-018-0176.
    >> Share

  157. PEETERS M, Price T, Taieb J, Geissler M, et al
    Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK
    Br J Cancer. 2018 Jul 17. pii: 10.1038/s41416-018-0165.
    >> Share

  158. ROSEWEIR AK, Halcrow ES, Chichilo S, Powell AG, et al
    ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer.
    Br J Cancer. 2018 Jul 10. pii: 10.1038/s41416-018-0174.
    >> Share

  159. BERGER AK, Lucke S, Abel U, Haag GM, et al
    Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
    Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0152.
    >> Share

    June 2018
  160. CHOI Y, Kwon CH, Lee SJ, Park J, et al
    Integrative analysis of oncogenic fusion genes and their functional impact in colorectal cancer.
    Br J Cancer. 2018 Jun 29. pii: 10.1038/s41416-018-0153.
    >> Share

  161. THOMSEN M, Skovlund E, Sorbye H, Bolstad N, et al
    Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome.
    Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0115.
    >> Share

  162. ZHENG R, Du M, Zhang B, Xin J, et al
    Body mass index (BMI) trajectories and risk of colorectal cancer in the PLCO cohort.
    Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0121.
    >> Share

    May 2018
  163. MORGAN RG, Mortensson E, Williams AC
    Targeting LGR5 in Colorectal Cancer: therapeutic gold or too plastic?
    Br J Cancer. 2018 May 30. pii: 10.1038/s41416-018-0118.
    >> Share

  164. SIRNIO P, Tuomisto A, Tervahartiala T, Sorsa T, et al
    High-serum MMP-8 levels are associated with decreased survival and systemic inflammation in colorectal cancer.
    Br J Cancer. 2018 May 29. pii: 10.1038/s41416-018-0136.
    >> Share

  165. NEUMEYER S, Banbury BL, Arndt V, Berndt SI, et al
    Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer.
    Br J Cancer. 2018 May 24. pii: 10.1038/s41416-018-0108.
    >> Share

  166. DOLAN RD, McSorley ST, Park JH, Watt DG, et al
    The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores.
    Br J Cancer. 2018 May 23. pii: 10.1038/s41416-018-0095.
    >> Share

  167. ZUNDER SM, van Pelt GW, Gelderblom HJ, Mancao C, et al
    Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0083.
    >> Share

  168. MA R, Xu L, Qu X, Che X, et al
    AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0086.
    >> Share

    April 2018
  169. BERGHEIM J, Semaan A, Gevensleben H, Groening S, et al
    Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.
    Br J Cancer. 2018 Apr 3. pii: 10.1038/s41416-018-0035.
    >> Share

    March 2018
  170. SHINOZAKI E, Yoshino T, Tsuchihara K
    Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Ant
    Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0040.
    >> Share

  171. DANKNER M, Rose AAN
    Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by
    Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0012.
    >> Share

  172. CREMOLINI C, Milione M, Marmorino F, Morano F, et al
    Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
    Br J Cancer. 2018 Mar 13. pii: 10.1038/s41416-018-0015.
    >> Share

  173. MORRIS JS, Bradbury KE, Cross AJ, Gunter MJ, et al
    Physical activity, sedentary behaviour and colorectal cancer risk in the UK Biobank.
    Br J Cancer. 2018 Mar 8. pii: bjc2017496. doi: 10.1038/bjc.2017.
    >> Share

  174. FERNANDEZ-ROZADILLA C, Kartsonaki C, Woolley C, McClellan M, et al
    Telomere length and genetics are independent colorectal tumour risk factors in an evaluation of biomarkers in normal bowel.
    Br J Cancer. 2018;118:727-732.
    >> Share

  175. DI GIROLAMO C, Walters S, Gildea C, Benitez Majano S, et al
    Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009-2013? Implications for use of the data in research.
    Br J Cancer. 2018;118:733-737.
    >> Share

  176. PATEL M, McSorley ST, Park JH, Roxburgh CSD, et al
    The relationship between right-sided tumour location, tumour microenvironment, systemic inflammation, adjuvant therapy and survival in patients undergoing surgery for colon and rectal cancer.
    Br J Cancer. 2018;118:705-712.
    >> Share

    February 2018
  177. MORGAN RG, Mortensson E, Legge DN, Gupta B, et al
    LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity.
    Br J Cancer. 2018;118:558-565.
    >> Share

  178. YUZHALIN AE, Urbonas T, Silva MA, Muschel RJ, et al
    A core matrisome gene signature predicts cancer outcome.
    Br J Cancer. 2018;118:435-440.
    >> Share

  179. NIEMINEN MT, Listyarifah D, Hagstrom J, Haglund C, et al
    Treponema denticola chymotrypsin-like proteinase may contribute to orodigestive carcinogenesis through immunomodulation.
    Br J Cancer. 2018;118:428-434.
    >> Share

    January 2018
  180. USHER-SMITH JA, Harshfield A, Saunders CL, Sharp SJ, et al
    External validation of risk prediction models for incident colorectal cancer using UK Biobank.
    Br J Cancer. 2018 Jan 30. pii: bjc2017463. doi: 10.1038/bjc.2017.
    >> Share

  181. TAPIAL S, Rueda D, Arriba M, Luis Garcia J, et al
    Comment on 'Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system'.
    Br J Cancer. 2018 Jan 2. pii: bjc2017343. doi: 10.1038/bjc.2017.
    >> Share

  182. FENG H, Zhao JK, Schiergens TS, Wang PX, et al
    Bone marrow-derived mesenchymal stromal cells promote colorectal cancer cell death under low-dose irradiation.
    Br J Cancer. 2018 Jan 2. pii: bjc2017415. doi: 10.1038/bjc.2017.
    >> Share

  183. BAE JM, Kim JH, Kwak Y, Lee DW, et al
    Reply to 'Comment on 'Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system".
    Br J Cancer. 2018 Jan 2. pii: bjc2017426. doi: 10.1038/bjc.2017.
    >> Share

    December 2017
  184. KIM SR, Song N, Yothers G, Gavin PG, et al
    Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology).
    Br J Cancer. 2017 Dec 14. pii: bjc2017448. doi: 10.1038/bjc.2017.
    >> Share

  185. FENG H, Liu Y, Bian X, Zhou F, et al
    ALDH1A3 affects colon cancer in vitro proliferation and invasion depending on CXCR4 status.
    Br J Cancer. 2017 Dec 12. pii: bjc2017363. doi: 10.1038/bjc.2017.
    >> Share

  186. DOPESO H, Rodrigues P, Bilic J, Bazzocco S, et al
    Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer.
    Br J Cancer. 2017 Dec 5. pii: bjc2017420. doi: 10.1038/bjc.2017.
    >> Share

  187. ALBUQUERQUE A, Pessegueiro Miranda H, Lopes J, Gandara J, et al
    Liver transplant recipients have a higher prevalence of anal squamous intraepithelial lesions.
    Br J Cancer. 2017;117:1761-1767.
    >> Share

  188. LIEVRE A, Ouine B, Canet J, Cartier A, et al
    Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
    Br J Cancer. 2017;117:1819-1827.
    >> Share

    November 2017
  189. PILLOZZI S, D'Amico M, Bartoli G, Gasparoli L, et al
    The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells.
    Br J Cancer. 2017 Nov 21. doi: 10.1038/bjc.2017.
    >> Share

  190. FLOUD S, Barnes I, Verfurden M, Kuper H, et al
    Disability and participation in breast and bowel cancer screening in England: a large prospective study.
    Br J Cancer. 2017;117:1711-1714.
    >> Share

  191. KAWAKITA D, Lee YA, Gren LH, Buys SS, et al
    The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.
    Br J Cancer. 2017 Nov 21. doi: 10.1038/bjc.2017.
    >> Share

  192. GOEL A
    IGF-1R: SUMO-ing its weight in chemoresistant colorectal cancer.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    >> Share

  193. CODONY-SERVAT J, Cuatrecasas M, Asensio E, Montironi C, et al
    Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    >> Share

  194. GOEY KKH, Elias SG, Hinke A, van Oijen MGH, et al
    Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    >> Share

  195. SCLAFANI F, Brown G, Cunningham D, Wotherspoon A, et al
    Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.
    Br J Cancer. 2017;117:1478-1485.
    >> Share

  196. COOPER JA, Parsons N, Stinton C, Mathews C, et al
    Risk-adjusted colorectal cancer screening using the FIT and routine screening data: development of a risk prediction model.
    Br J Cancer. 2017 Nov 2. doi: 10.1038/bjc.2017.
    >> Share

    October 2017
  197. MURAKAMI T, Kikuchi H, Ishimatsu H, Iino I, et al
    Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis.
    Br J Cancer. 2017;117:1360-1370.
    >> Share

  198. RUZZO A, Graziano F, Galli F, Galli F, et al
    Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
    Br J Cancer. 2017;117:1269-1277.
    >> Share

  199. HOU L, Zhu D, Liang Y, Tian X, et al
    Identification of a specific peptide binding to colon cancer cells from a phage-displayed peptide library.
    Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
    >> Share

  200. THERKILDSEN C, Ladelund S, Smith-Hansen L, Lindberg LJ, et al
    Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types.
    Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
    >> Share

  201. GOLLINS S, West N, Sebag-Montefiore D, Myint AS, et al
    Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.
    Br J Cancer. 2017;117:1286-1294.
    >> Share

  202. LETELLIER E, Schmitz M, Ginolhac A, Rodriguez F, et al
    Loss of Myosin Vb in colorectal cancer is a strong prognostic factor for disease recurrence.
    Br J Cancer. 2017 Oct 12. doi: 10.1038/bjc.2017.
    >> Share

  203. SHINOZAKI E, Yoshino T, Yamazaki K, Muro K, et al
    Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensi
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    >> Share

    September 2017
  204. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    >> Share

  205. BROWN JC, Zemel BS, Troxel AB, Rickels MR, et al
    Dose-response effects of aerobic exercise on body composition among colon cancer survivors: a randomised controlled trial.
    Br J Cancer. 2017 Sep 21. doi: 10.1038/bjc.2017.
    >> Share

  206. GIAMPIERI R, Puzzoni M, Daniele B, Ferrari D, et al
    First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) tr
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    >> Share

  207. SCHUBERT SA, Ruano D, Elsayed FA, Boot A, et al
    Evidence for genetic association between chromosome 1q loci and predisposition to colorectal neoplasia.
    Br J Cancer. 2017;117:876-884.
    >> Share

    August 2017
  208. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    >> Share

  209. ALLARD MA, Adam R, Giuliante F, Lapointe R, et al
    Long-term outcomes of patients with 10 or more colorectal liver metastases.
    Br J Cancer. 2017;117:604-611.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016